Xencor, Inc. (XNCR) Expected to Announce Quarterly Sales of $8.15 Million

Equities research analysts expect Xencor, Inc. (NASDAQ:XNCR) to announce $8.15 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Xencor’s earnings, with the highest sales estimate coming in at $10.30 million and the lowest estimate coming in at $6.00 million. Xencor posted sales of $7.82 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 4.2%. The company is scheduled to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Xencor will report full year sales of $8.15 million for the current financial year, with estimates ranging from $25.10 million to $38.30 million. For the next fiscal year, analysts expect that the company will report sales of $28.10 million per share, with estimates ranging from $20.00 million to $36.20 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Xencor.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million. Xencor had a negative net margin of 121.04% and a negative return on equity of 13.79%.

Several research firms recently commented on XNCR. Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Xencor in a research note on Friday, June 16th. BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Canaccord Genuity reissued a “buy” rating and set a $36.00 price objective on shares of Xencor in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $29.33.

Xencor (NASDAQ XNCR) opened at 21.73 on Friday. Xencor has a 52-week low of $18.45 and a 52-week high of $29.38. The stock’s 50 day moving average is $21.61 and its 200-day moving average is $22.66. The company’s market cap is $1.02 billion.

WARNING: This piece of content was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/09/17/xencor-inc-xncr-expected-to-announce-quarterly-sales-of-8-15-million.html.

In related news, major shareholder John S. Stafford III acquired 6,000 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was purchased at an average cost of $19.94 per share, with a total value of $119,640.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III acquired 27,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were bought at an average cost of $21.13 per share, with a total value of $570,510.00. The disclosure for this purchase can be found here. Insiders have bought 221,551 shares of company stock valued at $4,506,556 over the last three months. 4.03% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the business. Alps Advisors Inc. increased its holdings in Xencor by 0.3% during the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 52 shares during the last quarter. Falcon Point Capital LLC increased its holdings in Xencor by 0.5% during the second quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock valued at $614,000 after buying an additional 156 shares during the last quarter. Parametric Portfolio Associates LLC increased its holdings in Xencor by 0.6% during the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock valued at $867,000 after buying an additional 209 shares during the last quarter. Legal & General Group Plc increased its holdings in Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in Xencor by 2.3% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock valued at $492,000 after buying an additional 521 shares during the last quarter. 76.92% of the stock is owned by institutional investors and hedge funds.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply